Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID

Version 1 : Received: 30 June 2024 / Approved: 1 July 2024 / Online: 1 July 2024 (17:58:01 CEST)

How to cite: Dow, C. T. Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID. Preprints 2024, 2024070115. https://doi.org/10.20944/preprints202407.0115.v1 Dow, C. T. Proposing Bromo-Epi-Androsterone for Neurologic Long-COVID. Preprints 2024, 2024070115. https://doi.org/10.20944/preprints202407.0115.v1

Abstract

The neurologic effects of long-COVID are a therapeutic challenge. This article discusses the immunologic manifestations of long-COVID and proposes a non-androgenic, synthetic analog of dehydroepiandrosterone (DHEA), bromo-epi-androsterone (BEA), as a candidate for clinical trials for this exigent collection of neurologic conditions. Moreover, because there is an association between long-COVID and Alzheimer’s disease, the evaluation of BEA in long-COVID may serve as a proxy for its effect on neuroinflammatory biomarkers of Alzheimer’s disease that are shared with long-COVID.

Keywords

SARS-CoV-2; Long-COVID; brain fog, immune dysregulation, dehydroepiandrosterone (DHEA); bromo-epi-androsterone (BEA); biomarkers; neuroinflammation; Alzheimer’s.

Subject

Medicine and Pharmacology, Epidemiology and Infectious Diseases

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.